REYVOW Drug Patent Profile

When do Reyvow patents expire, and what generic alternatives are available?

Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-eight patent family members in forty-two countries.

The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.

DrugPatentWatch^® Generic Entry Outlook for Reyvow

Reyvow will be eligible for patent challenges on January 31, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 5, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for REYVOW

International Patents:	78
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	63
Patent Applications:	104
Drug Prices:	Drug price information for REYVOW
What excipients (inactive ingredients) are in REYVOW?	REYVOW excipients list
DailyMed Link:	REYVOW at DailyMed

See drug prices for REYVOW

DrugPatentWatch^® Estimated Generic Entry Opportunity Date for REYVOW

NDA:

211280

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for REYVOW

N02CC	Selective serotonin (5HT1) agonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

US Patents and Regulatory Information for REYVOW

REYVOW is protected by three US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting REYVOW

FDA Regulatory Exclusivity protecting REYVOW

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-001	Jan 31, 2020		RX	Yes	No
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-002	Jan 31, 2020		RX	Yes	Yes			Y	Y
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-001	Jan 31, 2020		RX	Yes	No
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-003	Dec 18, 2020		DISCN	Yes	No

International Patents for REYVOW

When does loss-of-exclusivity occur for REYVOW?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Jordan

Lithuania

Mexico

Moldova, Republic of

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering REYVOW around the world.

Country	Patent Number	Title	Estimated Expiration
Chile	2019001426	Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.
Taiwan	I263497
World Intellectual Property Organization (WIPO)	2018106657
Mexico	PA04009497	PIRIDINOILPIPERIDINAS COMO ANTAGONISTAS DE 5-HT1F. (PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS.)